New dissertation on the treatment of malignant melanoma

December 6, 2017, Uppsala University

Malignant melanoma is one of the most common causes of cancer deaths among young adults. Although treatment for melanoma has improved in recent years, most patients do not benefit from the treatment, which also often causes side effects. In a new dissertation from Uppsala University, Aglaia Schiza has examined new ways of treating the disease.

If has spread, the prognosis is not good. That is why it is imperative to develop better strategies. One new treatment strategy for is to use the body's own immune system. Melanoma is considered a promising form of cancer for immunostimulatory gene therapy, which means that the immune system is activated to kill the cancer. CD40L is an immunostimulatory molecule that can, with the help of the virus, be introduced into the tumour, where it can stimulate the immune defences against the cancer cells.

Aglaia Schiza and her colleagues conducted a study in which with disseminated who had received established treatment were treated with injections in metastases of a virus-carrying gene for CD40L (AdCD40L). The goal was for the immunostimulatory molecule to not only work locally, but to also have a vaccinating and thereby affect metastases in the rest of the body. The majority of the patients also received low-dose cyclophosphamide along with the injections. In this low dose, the cytotoxic agent has no effect on the cancer, but can strengthen the effect of immunological treatment.

The treatment led to mild transient side effects. The patients who received both cyclophosphamide and AdCD40L immunotherapy had a better survival rate than those who only received AdCD40L.

"With the aid of radiography, we saw that, in addition to the injected metastasis, the treatment also affected others," says Aglaia Schiza, PhD student at the Department of Immunology, Genetics and Pathology at Uppsala University. "We also showed that the treatment gave desirable immune effects by stimulating good immune cells and inhibiting cells that counteract immune response. Using diffusion-weighted MRI, we could identify at an earlier stage which patients had a better chance of benefiting from AdCD40L treatment."

The dissertation also describes two cases of patients with disseminated melanoma who were treated with the BRAF-inhibitor vemurafenib outside indication (i.e. in situations in which vemurafenib is not approved due to as-yet insufficient findings). Half of all patients with melanoma have a mutation in their tumour in a gene that codes for the BRAF protein that is part of an important signal chain in the cancer cell. These patients can be treated with BRAF-inhibiting drugs. Schiza and her colleagues studied rare cases of disseminated BRAF-mutated melanoma in individual patients because the extremely low prevalence does not allow for any clinical trials. For the first time ever, a case of a pregnant woman treated with BRAF-inhibitors was reported. The treatment enabled a longer gestation and thereby less risk of immaturity-related complications. The dissertation also contains the first-ever report of successful treatment with vemurafenib by a patient with disseminated .

Explore further: Role of melanoma-promoting protein revealed

More information: Experimental treatment of patients with disseminated malignant melanoma. uu.diva-portal.org/smash/recor … fRows=50&dswid=-2989

Related Stories

Role of melanoma-promoting protein revealed

December 6, 2017
In a new study, Yale researchers describe the role of a protein that promotes growth of melanoma, the deadliest form of skin cancer.

New insight into drug resistance in metastatic melanoma

June 3, 2014
(Medical Xpress)—A study by scientists in Manchester has shown how melanoma drugs can cause the cancer to progress once a patient has stopped responding to treatment.

New drug, Vemurafenib, doubles survival of metastatic melanoma patients

March 1, 2012
A report published this week in the New England Journal of Medicine shows that the 50 percent of metastatic melanoma patients with a specific genetic mutation benefit from the drug Vemurafenib – increasing median survival ...

Immune and targeted therapies with radiation therapy improves outcomes for melanoma brain metastases patients

September 21, 2016
Brain metastases are one of the most common complications of advanced melanoma, requiring multidisciplinary management. Patients who are diagnosed with these metastases have an expected median survival of only 4 to 5 months. ...

Researchers discover mechanism leading to BRAF inhibitor resistance in melanoma

June 19, 2015
The development of targeted therapies has significantly improved the survival of melanoma patients over the last decade; however, patients often relapse because many therapies do not kill all of the tumor cells, and the remaining ...

Researchers find immunotherapy treatments better for advanced skin cancer

November 4, 2016
McMaster University researchers have found that for patients diagnosed in the late stages of one of the most common and deadly forms of skin cancer, treatment with a combination of immunotherapy options improves survival ...

Recommended for you

Resetting the epigenetic balance for cancer therapy

May 22, 2018
Though mutations in a gene called MLL3 are common across many types of cancers, their relationship to the development of the disease has been unclear. Now, a Northwestern Medicine study has identified an epigenetic imbalance ...

Compound in citrus oil could reduce dry mouth in head, neck cancer patients

May 21, 2018
A compound found in citrus oils could help alleviate dry mouth caused by radiation therapy in head and neck cancer patients, according to a new study by researchers at the Stanford University School of Medicine.

Ice cream funds research showing new strategy against thyroid cancer

May 21, 2018
Anaplastic thyroid cancer is almost uniformly fatal, with an average lifespan of about 5 months after diagnosis. And standard treatment for the condition includes 7 weeks of radiation, often along with chemotherapy.

Bladder cancer model could pave the way for better drug efficacy studies

May 21, 2018
Understanding that not all bladder cancers are the same, researchers at the University of North Carolina Lineberger Comprehensive Cancer Center have created a tool that may help them to uncover why only a fraction of patients ...

Breath test breakthrough for early diagnosis of oesophageal and gastric cancer

May 18, 2018
A breath test can successfully detect oesophageal and gastric cancer and could be used as a first-line test for patients, say researchers.

MR spectroscopy imaging reveals effects of targeted treatment of mutant IDH1 gliomas

May 18, 2018
Using a novel imaging method, a Massachusetts General Hospital (MGH) research team is investigating the mechanisms behind a potential targeted treatment for a subtype of the deadly brains tumors called gliomas. In their report ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.